bupropion
DrugExtended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
Other names: Wellbutrin, Zyban
NCT Number: NCT05205811
This three-group randomized double-blind placebo-controlled trial (N=180) will evaluate the impact of combination zonisamide and bupropion on the process of switching from combustible cigarettes (CCs) to an e-cigarette. There will be a data collection period of at least five days to obtain baseline information on the use of combustible cigarettes. All participants enrolled in the study will receive a JUUL e-cigarette at Visit 2 for ad libitum use. After the first week of e-cigarette use (at Visit 3), participants will be given bupropion (150 mg each morning for days 1-3, then 300 mg daily) with either zonisamide (100 mg daily) or placebo (group 1 and group 2 respectively), or placebo for both medications (group 3) in addition to continued use of the e-cigarette. At each visit, participants will receive enough study drugs (or placebos) and e-cigarettes to last until their next study visit. The combination of zonisamide and bupropion use will continue until Visit 6 (7 weeks of treatment), and e-cigarette use will continue until the end of treatment (Visit 7).
Looking for future studies?
Notify Me21 year–65 year
All sexes
Interventional
Phase 3
Rose Research Center, Charlotte, North Carolina, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Extended-release bupropion dosing (150 mg each morning days 1-3, then 300 mg/daily) for the remainder of the 7 weeks.
Other names: Wellbutrin, Zyban
Zonisamide (100 mg/daily) for 7 weeks.
Other names: zonegran
Placebo bupropion for 7 weeks.
Placebo zonisamide for 7 weeks.
e-cigarette for ad libitum use for two weeks prior to complete switch day and for an additional 10 weeks.
Other names: JUUL
Time frame: After 8 weeks
Exhaled carbon monoxide (CO) < 5 ppm at the end of drug treatment
Time frame: Baseline, Week 8, Week 12
Total urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL)
Time frame: Daily from Week 2 to Week 12
Self-report of daily cigarette and e-cigarette use
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
Smoking withdrawal symptoms will be collected using a questionnaire developed by Drs. Shiffman and Jarvik (1976), which assesses craving for cigarettes, negative mood, arousal, missing the habit of smoking, changes in appetite and somatic symptoms and a seven-point scale (from 1-Not at All to 7-Extremely). Higher scores indicate more withdrawal symptoms.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8, Week 12
The mCEQ-E will be utilized to assess the degree to which participants experience the reinforcing of smoking, providing five subscale scores: smoking satisfaction (satisfying, tastes good,enjoy smoking), psychological rewards (calms down, more awake, less irritable, helps concentrate, reduces hunger), aversion (dizziness, nauseated), enjoyment of respiratory tract sensations (single-item assessment), craving reduction (single-item assessment). Participants will be asked to assess the 12 items of the questionnaire on a 7-point scale, ranging from "not at all" to "extremely". These 12 items will be asked for the "first cigarette smoked", "cigarette immediately after a meal", and "all other cigarettes." The e-cigarette version of this questionnaire (mECEQ-E) will also be used.
Time frame: Baseline, Week 1, Week 2, Week 4, Week 8
The frequency of drug termination or non-adherence prior to Week 8 will be tabulated for each condition. Adverse effects will also be tabulated for each condition, including the following adverse effects of special interest (AESIs): insomnia, agitation, dry mouth, somnolence, headache, nausea, constipation, diarrhea, dizziness or loss of appetite.
Time frame: 6 Months post Switch Day
Seven-day point abstinence at 6 months post-switch will be assessed by self-report and confirmed by exhaled carbon monoxide (CO) < 5 ppm.
Rose Research Center, LLC
Industry
A Randomized Controlled Trial to Determine the Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06027840
Behavior, Cigarette Smoking
New Haven, Connecticut, United States
View Trial DetailsNCT04854616
Behavior, Disease Attributes
Norwich, Norfolk, United Kingdom
View Trial DetailsNCT06087328
Behavior, Cigarette Smoking
Charleston, South Carolina, United States
View Trial DetailsNCT04188197
Behavior, Chemically-Induced Disorders
Charlotte, North Carolina, United States
View Trial Details